Drug Type Recombinant protein |
Synonyms Cerenis HDL, Recombinant Human Apolipoprotein A-I, Recombinant Human Apolipoprotein A-I/Phospholipids complex + [2] |
Target |
Mechanism APOA1 stimulants(Apolipoprotein A-I stimulants), SCARB1 agonists(Scavenger receptor class B member 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Coronary Syndrome | Phase 2 | - | - | |
Atherosclerosis | Phase 2 | - | - | |
Familial HDL Deficiency | Preclinical | BE | 01 Dec 2015 | |
Familial HDL Deficiency | Preclinical | CA | 01 Dec 2015 | |
Familial HDL Deficiency | Preclinical | US | 01 Dec 2015 | |
Familial HDL Deficiency | Preclinical | FR | 01 Dec 2015 | |
Familial HDL Deficiency | Preclinical | IL | 01 Dec 2015 | |
Familial HDL Deficiency | Preclinical | IT | 01 Dec 2015 | |
Familial HDL Deficiency | Preclinical | NL | 01 Dec 2015 | |
Homozygous familial hypercholesterolemia | Discovery | GB | 01 Nov 2011 |
Phase 2 | 20 | (pcqnnvwzah) = no serious adverse events were attributed to CER-001 use luzkzzhazj (yzgrpvfcwo ) | Positive | 02 Nov 2023 | |||
standard of care | |||||||
Phase 2 | 293 | (ixcuxtihxv) = kcfaidjxse zzkldlslgv (npbriihnfl ) View more | Negative | 01 Sep 2018 | |||
Placebo | (ixcuxtihxv) = uuuormpgdj zzkldlslgv (npbriihnfl ) View more | ||||||
Phase 2 | 23 | quwcabuiqe(wxwcfiduvk) = kiwldqedhx odjokszcmk (ssauvnfezu ) | Positive | 01 May 2015 | |||
Phase 2 | 507 | Placebo | (afowuheoac) = gtuvcmhlqo wpwrdzvnhy (vytmixtpnk ) View more | - | 07 Dec 2014 | ||
(afowuheoac) = omobxfmprn wpwrdzvnhy (vytmixtpnk ) View more |